Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan Emberson

Showing results (51-60 of 109) with videos related to

Pageof 11
Sort By:
BMC Nephrology|May 1, 2015
What is the impact of chronic kidney disease stage and cardiovascular disease on the annual cost of hospital care in moderate-to-severe kidney disease?Seamus Kent, Iryna Schlackow, Jingky Lozano-Kühne, et al.
Pharmacoeconomics|February 24, 2023
Prediction Models for Individual-Level Healthcare Costs Associated with Cardiovascular Events in the UKJunwen Zhou, Runguo Wu, Claire Williams, et al.
Kidney International Reports|June 2, 2018
Impact of CKD on Household IncomeRachael L Morton, Iryna Schlackow, Alastair Gray, et al.
The British Journal of General Practice : the Journal of the Royal College of General Practitioners|February 19, 2024
Long-term cardiovascular risks and the impact of statin treatment on socioeconomic inequalities: a microsimulation modelRunguo Wu, Claire Williams, Junwen Zhou, et al.
NEJM Evidence|June 21, 2024
Effect of Fenofibrate on Progression of Diabetic RetinopathyDavid Preiss, Jennifer Logue, Emily Sammons, et al.
International Journal of Epidemiology|November 30, 2017
Cohort Profile: The Korean Cancer Prevention Study-II (KCPS-II) BiobankYon Ho Jee, Jonathan Emberson, Keum Ji Jung, et al.
Lancet (London, England)|June 2, 2009
Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials, Colin Baigent, Lisa Blackwell, et al.
Kidney International|November 18, 2017
Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammationBenjamin C Storey, Natalie Staplin, Richard Haynes, et al.
Health Technology Assessment (Winchester, England)|December 7, 2024
Assessing long-term effectiveness and cost-effectiveness of statin therapy in the UK: a modelling study using individual participant data setsBorislava Mihaylova, Runguo Wu, Junwen Zhou, et al.
The Lancet Regional Health. Europe|March 29, 2024
Lifetime effects and cost-effectiveness of standard and higher-intensity statin therapy across population categories in the UK: a microsimulation modelling studyBorislava Mihaylova, Runguo Wu, Junwen Zhou, et al.
Pageof 11

Showing results (51-60 of 109) with videos related to

Sort By:
Pageof 11
BMC Nephrology|May 1, 2015
What is the impact of chronic kidney disease stage and cardiovascular disease on the annual cost of hospital care in moderate-to-severe kidney disease?Seamus Kent, Iryna Schlackow, Jingky Lozano-Kühne, et al.
Pharmacoeconomics|February 24, 2023
Prediction Models for Individual-Level Healthcare Costs Associated with Cardiovascular Events in the UKJunwen Zhou, Runguo Wu, Claire Williams, et al.
Kidney International Reports|June 2, 2018
Impact of CKD on Household IncomeRachael L Morton, Iryna Schlackow, Alastair Gray, et al.
The British Journal of General Practice : the Journal of the Royal College of General Practitioners|February 19, 2024
Long-term cardiovascular risks and the impact of statin treatment on socioeconomic inequalities: a microsimulation modelRunguo Wu, Claire Williams, Junwen Zhou, et al.
NEJM Evidence|June 21, 2024
Effect of Fenofibrate on Progression of Diabetic RetinopathyDavid Preiss, Jennifer Logue, Emily Sammons, et al.
International Journal of Epidemiology|November 30, 2017
Cohort Profile: The Korean Cancer Prevention Study-II (KCPS-II) BiobankYon Ho Jee, Jonathan Emberson, Keum Ji Jung, et al.
Lancet (London, England)|June 2, 2009
Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials, Colin Baigent, Lisa Blackwell, et al.
Kidney International|November 18, 2017
Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammationBenjamin C Storey, Natalie Staplin, Richard Haynes, et al.
Health Technology Assessment (Winchester, England)|December 7, 2024
Assessing long-term effectiveness and cost-effectiveness of statin therapy in the UK: a modelling study using individual participant data setsBorislava Mihaylova, Runguo Wu, Junwen Zhou, et al.
The Lancet Regional Health. Europe|March 29, 2024
Lifetime effects and cost-effectiveness of standard and higher-intensity statin therapy across population categories in the UK: a microsimulation modelling studyBorislava Mihaylova, Runguo Wu, Junwen Zhou, et al.
Pageof 11